Drug updated on 11/14/2023
|Dosage Form||Capsule (oral: 100 mg)|
|Drug Class||Kinase inhibitors|
- For treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer as detected by an FDA approved test (NSCLC).
- For treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy.
- For treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).
Product Monograph / Prescribing Information
|Gavreto (pralsetinib) Prescribing Information.||2022||Genentech, Inc., South San Francisco, CA|
Systematic Reviews / Meta-Analyses
|Clinical, pharmacoeconomic, and stakeholder input combined report.||2023||CADTH|
|Efficacy and Safety of RET-Specific Kinase Inhibitors in RET-Altered Cancers: A Systematic Review.||2023||Cancer investigation|
|Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer.||2022||NICE|
|Assessment report: Gavreto.||2021||EMA|
Ongoing and completed studies: ClinicalTrials.gov
Clinical Practice Guidelines
|Therapy for stage iv non–small-cell lung cancer with driver alterations: ASCO living guideline.||2022||Journal of Clinical Oncology|
|2021 American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer.||2021||Thyroid|
|NCCN guidelines insights: non–small cell lung cancer, version 2.2021.||2021||Journal of the National Comprehensive Cancer Network|
|Treating non-small cell lung cancer.||2020||American Cancer Society|